3 active not recruiting, 3 completed, 1 not yet recruiting, 1 recruiting. 6 Phase 1, 5 Phase 2, 3 Phase 3.
Follow Recurrent Classic Hodgkin Lymphoma: new trials by email Literature Review of Recurrent Classic Hodgkin Lymphoma trials Research Report on Recurrent Classic Hodgkin Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma 3-Dimensional Conformal Radiation Therapy, Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 374 | 2026-12-04 | 2026-07-08 |
| A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Bendamustine, Brentuximab Vedotin - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 3 | Withdrawn | National Cancer Institute (NCI) | 2023-08-10 | 2024-03-20 | |
| GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL) GLS-010, Chemotherapy of Investigator's choice - Classic Hodgkin's Lymphoma, Recurrent Classic Hodgkin Lymphoma | Phase 3 | Unknown | Guangzhou Gloria Biosciences Co., Ltd. | 60 | 2022-09-01 | 2022-08-26 |
| Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors Brentuximab Vedotin, Hematopoietic Cell Transplantation, Nivolumab - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 | Recruiting | Emory University | 46 | 2022-05-02 | 2026-09-08 |
| CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed Nivolumab, Oral Azacitidine - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 33 | 2022-01-03 | 2026-06-03 |
| Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine - Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 45 | 2020-07-18 | 2026-09-30 |
| Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat - Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL | Phase 1 | Active not recruiting | City of Hope Medical Center | 52 | 2017-07-18 | 2026-08-21 |
| Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer Antiretroviral Therapy, Biopsy, Biospecimen Collection - AIDS-Related Non-Hodgkin Lymphoma, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 1 | Completed | National Cancer Institute (NCI) | 58 | 2016-04-04 | 2024-08-09 |
| Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Advanced Malignant Solid Neoplasm, Anal Carcinoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 79 | 2015-10-21 | 2026-01-21 |
| Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Biopsy Procedure, Biospecimen Collection, Brentuximab Vedotin - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 146 | 2014-03-07 | 2026-10-22 |
| Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment. Bortezomib, Carboplatin, Etoposide - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 20 | 2009-08-24 | 2020-04-20 |
HIV Infections (2) · Lung Neoplasms (2) · Lymphoma, B-Cell (2) · Neoplasm Metastasis (2) · Recurrence (2) · Sarcoma, Kaposi (2) · Anus Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Melanoma (1)
Immune System Diseases (4) · Neoplasms by Histologic Type (4) · Hemic and Lymphatic Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Blood-Borne Infections (2) · Communicable Diseases (2) · DNA Virus Infections (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2)
Magnetic Resonance Spectroscopy (5) · Nivolumab (5) · Brentuximab Vedotin (4) · Specimen Handling (4) · pembrolizumab (4) · Biopsy (3) · Stem Cell Transplantation (3) · CTLA-4 Antigen (2) · Carboplatin (2) · Etoposide (2) · Ifosfamide (2) · Ipilimumab (2) · AFM13 (1) · Antiretroviral Therapy, Highly Active (1) · Azacitidine (1)
National Cancer Institute (NCI) (5) · City of Hope Medical Center (2) · M.D. Anderson Cancer Center (2) · Emory University (1) · Guangzhou Gloria Biosciences Co., Ltd. (1)
United States (8) · Australia (1)
Vaishalee P Kenkre (2) · Alex F Herrera (1) · Catherine S Diefenbach (1) · Kathryn Lurain (1) · Kristie Blum, MD (1) · Lakshmi Rajdev (1) · Matthew Mei, MD (1) · Michelle Fanale (1) · Yago L Nieto (1)
PMID 31154457, PMID 32853585, PMID 33677480, PMID 35080914, PMID 37339586, PMID 37470137, PMID 37505794, PMID 37962072, PMID 38737792, PMID 38934093, PMID 39356983, PMID 40186077, PMID 41662628, PMID 41680482
U10CA180820 (3), P30CA015704 (1), P30CA016672 (1), P30CA033572 (1), P30CA138292 (1), U01CA121947 (1), U01CA154967 (1), U24CA196172 (1), UM1CA121947 (1)